New research at Wake Forest University Baptist Medical Center suggests that a three-drug cocktail may one day improve outcomes in patients with glioblastoma multiforme (GBM), a type of brain tumor with a dismal prognosis.

A clinical study conducted at Henry Ford Hospital on the use of a drug to extend the survival of patients with the most common and aggressive type of brain cancer, has yielded results that were significantly better than expected.

Results of Avastin phase II trial from Genentech slow down aggressive brain cancer in phase II study and could possibly provide brain cancer treatment.

Australian researchers have identified five genes which they hope will improve treatment for people with brain tumours.

A gene linked to pediatric brain tumors is an essential driver of early brain development, researchers at Washington University School of Medicine in St. Louis have found.

A new drug-delivery system for cancer of the brain — one of the most difficult cancers to treat — has the potential to carry anticancer drugs 10 times deeper into tumors than conventional medications, researchers in Connecticut and New York report. Their study is scheduled for the Nov./Dec. issue of ACS’ Bioconjugate Chemistry, a bi-monthly journal.

Specifically aimed, “stereotactic” radiation may be as good as surgery – and in some cases, even better – in treating benign but potentially devastating brain tumors called non-acoustic schwannomas, according to a study by radiation oncologists at the Kimmel Cancer Center at Thomas Jefferson University and Thomas Jefferson University Hospital in Philadelphia.

Over four times as many patients with a rapidly fatal type of brain cancer, glioblastoma multiforme (GBM), who are treated with the chemotherapy drug temozolomide (TMZ) and radiation therapy, can live for four years after diagnosis, compared to those who receive only radiation treatment.

A common human virus may prove useful in attacking the deadliest form of brain tumors, according to study conducted by researchers at Duke's Preston Robert Tisch Brain Tumor Center. The researchers said the finding is an important step in developing a vaccine that can attack the tumors by enlisting the help of the body's immune system.

A vaccine that has significantly increased life expectancy in early tests of patients with glioblastoma multiforme (GBM) − the most common, most aggressive form of brain cancer in adults − is now being offered through a clinical trial at Mayo Clinic in Jacksonville.

A clinical trial evaluating a brain cancer vaccine in patients with newly diagnosed brain cancer has begun at NYU Medical Center. The study will evaluate the addition of the vaccine following standard therapy with surgery and chemotherapy in patients with glioblastoma multiforme, a deadly form of brain cancer.

Brain cancer patients with the poorest prognosis -- those with a type of deadly tumor known as glioblastoma multiforme (GBM) -- may survive longer with a drug that chokes off a tumor’s blood supply.